PURPOSE: Controversy exists regarding the use of continuous antibiotic prophylaxis vs observation in the management of children with vesicoureteral reflux. The reported effectiveness of continuous antibiotic prophylaxis in children with reflux varies widely. We determined whether the aggregated evidence supports use of continuous antibiotic prophylaxis in children with vesicoureteral reflux. MATERIALS AND METHODS: We searched the Cochrane Controlled Trials Register, clinicaltrials.gov, MEDLINE(®), EMBASE(®), Google Scholar and recently presented meeting abstracts for reports in any language. Bibliographies of included studies were then hand searched for any missed articles. The study protocol was prospectively registered at PROSPERO (No. CRD42014009639). Reports were assessed and data abstracted in duplicate, with differences resolved by consensus. Risk of bias was assessed using standardized instruments. RESULTS: We identified 1,547 studies, of which 8 are included in the meta-analysis. Pooled results demonstrated that continuous antibiotic prophylaxis significantly reduced the risk of recurrent febrile or symptomatic urinary tract infection (pooled OR 0.63, 95% CI 0.42-0.96) but, if urinary tract infection occurred, increased the risk of antibiotic resistant organism (pooled OR 8.75, 95% CI 3.52-21.73). A decrease in new renal scarring was not associated with continuous antibiotic prophylaxis use. Adverse events were similar between the 2 groups. Significant heterogeneity existed between studies (I(2) 50%, p = 0.03), specifically between those trials with significant risk of bias (eg unclear protocol descriptions and/or lack of blinding). CONCLUSIONS: Compared to no treatment, continuous antibiotic prophylaxis significantly reduced the risk of febrile and symptomatic urinary tract infections in children with vesicoureteral reflux, although it increased the risk of infection due to antibiotic resistant bacteria. Continuous antibiotic prophylaxis did not significantly impact the occurrence of new renal scarring or reported adverse events.
PURPOSE: Controversy exists regarding the use of continuous antibiotic prophylaxis vs observation in the management of children with vesicoureteral reflux. The reported effectiveness of continuous antibiotic prophylaxis in children with reflux varies widely. We determined whether the aggregated evidence supports use of continuous antibiotic prophylaxis in children with vesicoureteral reflux. MATERIALS AND METHODS: We searched the Cochrane Controlled Trials Register, clinicaltrials.gov, MEDLINE(®), EMBASE(®), Google Scholar and recently presented meeting abstracts for reports in any language. Bibliographies of included studies were then hand searched for any missed articles. The study protocol was prospectively registered at PROSPERO (No. CRD42014009639). Reports were assessed and data abstracted in duplicate, with differences resolved by consensus. Risk of bias was assessed using standardized instruments. RESULTS: We identified 1,547 studies, of which 8 are included in the meta-analysis. Pooled results demonstrated that continuous antibiotic prophylaxis significantly reduced the risk of recurrent febrile or symptomatic urinary tract infection (pooled OR 0.63, 95% CI 0.42-0.96) but, if urinary tract infection occurred, increased the risk of antibiotic resistant organism (pooled OR 8.75, 95% CI 3.52-21.73). A decrease in new renal scarring was not associated with continuous antibiotic prophylaxis use. Adverse events were similar between the 2 groups. Significant heterogeneity existed between studies (I(2) 50%, p = 0.03), specifically between those trials with significant risk of bias (eg unclear protocol descriptions and/or lack of blinding). CONCLUSIONS: Compared to no treatment, continuous antibiotic prophylaxis significantly reduced the risk of febrile and symptomatic urinary tract infections in children with vesicoureteral reflux, although it increased the risk of infection due to antibiotic resistant bacteria. Continuous antibiotic prophylaxis did not significantly impact the occurrence of new renal scarring or reported adverse events.
Authors: Joshua J Fenton; Sohail K Mirza; Amnon Lahad; Benjamin D Stern; Richard A Deyo Journal: Spine (Phila Pa 1976) Date: 2007-02-15 Impact factor: 3.468
Authors: Bruno Leslie; Katherine Moore; Joao L Pippi Salle; Antoine E Khoury; Anthony Cook; Luis H P Braga; Darius J Bägli; Armando J Lorenzo Journal: J Urol Date: 2010-07-21 Impact factor: 7.450
Authors: C William Schwab; Hsi-Yang Wu; Heather Selman; Grahame H H Smith; Howard M Snyder; Douglas A Canning Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Eduardo H Garin; Fernando Olavarria; Victor Garcia Nieto; Blanca Valenciano; Alfonso Campos; Linda Young Journal: Pediatrics Date: 2006-03 Impact factor: 7.124
Authors: Alejandro Hoberman; Martin Charron; Robert W Hickey; Marc Baskin; Diana H Kearney; Ellen R Wald Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Rachel E Selekman; Daniel J Shapiro; John Boscardin; Gabrielle Williams; Jonathan C Craig; Per Brandström; Marco Pennesi; Gwenalle Roussey-Kesler; Pankaj Hari; Hillary L Copp Journal: Pediatrics Date: 2018-07 Impact factor: 7.124
Authors: Zachary R Dionise; Juan Marcos Gonzalez; Michael L Garcia-Roig; Andrew J Kirsch; Charles D Scales; John S Wiener; J Todd Purves; Jonathan C Routh Journal: Urology Date: 2019-03-14 Impact factor: 2.649
Authors: Andrew L Schwaderer; Huanyu Wang; SungHwan Kim; Jennifer M Kline; Dong Liang; Pat D Brophy; Kirk M McHugh; George C Tseng; Vijay Saxena; Evan Barr-Beare; Keith R Pierce; Nader Shaikh; J Robert Manak; Daniel M Cohen; Brian Becknell; John D Spencer; Peter B Baker; Chack-Yung Yu; David S Hains Journal: J Am Soc Nephrol Date: 2016-03-03 Impact factor: 10.121
Authors: Tej K Mattoo; Russell W Chesney; Saul P Greenfield; Alejandro Hoberman; Ron Keren; Ranjiv Mathews; Lisa Gravens-Mueller; Anastasia Ivanova; Myra A Carpenter; Marva Moxey-Mims; Massoud Majd; Harvey A Ziessman Journal: Clin J Am Soc Nephrol Date: 2015-11-10 Impact factor: 8.237
Authors: Jonathan C Routh; Earl Y Cheng; J Christopher Austin; Michelle A Baum; Patricio C Gargollo; Richard W Grady; Adrienne R Herron; Steven S Kim; Shelly J King; Chester J Koh; Pangaja Paramsothy; Lisa Raman; Michael S Schechter; Kathryn A Smith; Stacy T Tanaka; Judy K Thibadeau; William O Walker; M Chad Wallis; John S Wiener; David B Joseph Journal: J Urol Date: 2016-07-27 Impact factor: 7.450